YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment

This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with metastatic colorectal cancer.

Trial Details

NCT ID

NCT07409805

Phase

PHASE1

Sponsor

West China Hospital

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

YMN-136 Vaccine

Locations (sample)

Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Voluntarily sign the informed consent form, be able to understand and agree to follow the prescribed research procedures and visits;
Aged 18-75 years, both male and female are eligible;
Histologically confirmed unresectable advanced colorectal adenocarcinoma;
Patients with colorectal cancer liver metastasis who have failed third-line treatment, defined as those who have experienced disease progression (b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →